TMCnet News

Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Analysis 2017: Key Players are Alkermes, Reata Pharmaceuticals, Incuron, Catabasis Pharmaceuticals - Research and Markets
[December 13, 2017]

Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Analysis 2017: Key Players are Alkermes, Reata Pharmaceuticals, Incuron, Catabasis Pharmaceuticals - Research and Markets


The "Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Analysis, 2017" report has been added to Research and Markets' offering.

The study analyzed that the NF-kB inhibitors therapeutics pipeline comprises approximately 17 drug candidates in different stages of development. Nuclear factor-kappa B (NF-kB) is the transcription factor which is involved in the regulation of over 500 genes, that are responsible for cell proliferation, survival, invasion, metastasis, angiogenesis and inflammation. Therefore, development of therapeutics that acts as NF-kB inhibitors, can treat various diseases including cancer and chronic inflammation.

According to the research findings, most of the drug candidates in the NF-kB inhibitors therapeutics pipeline are being developed as small molecule using synthetic source. /p>



According to the National Cancer Institute, the prevalence of cancer has been increasing at a very high rate. Therefore, companies are focusing on developing target specific and personalized medicine for the better treatment with reduced adverse events. Thus, NF-kB inhibitors therapeutics pipeline is likely to grow significantly, in the future, for the treatment of various diseases including cancer and chronic inflammation.

Some of the key players developing drugs as NF-kB inhibitors for the treatment of various indications include Alkermes Plc, Reata Pharmaceuticals, Inc., Incuron LLC, Catabasis Pharmaceuticals, Inc. and others.


NF-kB Inhibitors Therapeutics Pipeline Analysis:

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

Key Topics Covered:

1. Research Background

2. Research Methodology

3. Executive Summary

4. Pipeline Outlook

5. NF-Kappa B Inhibitors Therapeutics Pipeline Analysis by Phase (2017)

6. Clinical Trials Analysis

7. Competitive Landscape

8. Company Profiles

9. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/hwpzkw/nuclear?w=4


[ Back To TMCnet.com's Homepage ]